Online inquiry

IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10564MR)

This product GTTS-WQ10564MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10564MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11305MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-522
GTTS-WQ2672MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ6074MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ15556MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ1143MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ14136MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ13253MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ3693MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 2287409
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW